Prime Medicine, Inc. (PRME) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 5 recommend buying, 4 recommend holding, and 0 recommend selling.
The analyst consensus price target for PRME is $17.25, representing a +366.2% upside from the current price of $3.7. Price targets range from a low of $12.00 to a high of $23.00.
